Imunon, Inc. (NASDAQ:IMNN – Get Free Report) shot up 1.4% during mid-day trading on Friday . The stock traded as high as $1.5301 and last traded at $1.47. 129,166 shares changed hands during mid-day trading, an increase of 25% from the average daily volume of 103,466 shares. The stock had previously closed at $1.45.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.
Get Our Latest Research Report on Imunon
Imunon Price Performance
Imunon (NASDAQ:IMNN – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.33. Equities analysts predict that Imunon, Inc. will post -2.37 earnings per share for the current fiscal year.
Institutional Trading of Imunon
An institutional investor recently bought a new stake in Imunon stock. Armistice Capital LLC bought a new stake in shares of Imunon, Inc. (NASDAQ:IMNN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned about 8.69% of Imunon as of its most recent filing with the Securities and Exchange Commission. 4.47% of the stock is owned by hedge funds and other institutional investors.
About Imunon
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
Featured Stories
- Five stocks we like better than Imunon
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
